To include your compound in the COVID-19 Resource Center, submit it here.

Zonegran zonisamide: Phase III data

Eisai said it submitted a regulatory application in Europe for Zonegran as a first-line monotherapy in newly diagnosed adults with epilepsy, but would not disclose when. Eisai markets Zonegran in

Read the full 300 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE